FXI

COVID-19 Impacts: Spray Polyurethane Foam Will Accelerate at a CAGR of Over 7% Through 2020-2024 | Demand for Spray PU Foams in Construction Industry to Boost Growth | Technavio

Retrieved on: 
월요일, 8월 10, 2020
Chemicals, Plastics, Other Construction & Property, Residential Building & Real Estate, Manufacturing, Commercial Building & Real Estate, Construction & Property, Building insulation materials, Plastics, Physical sciences, Covestro, Chemistry, Polyurethane, Materials, Foam, FXI, Sekisui Chemical

Our spray polyurethane foam report covers the following areas:

Key Points: 
  • Our spray polyurethane foam report covers the following areas:
    This study identifies innovations in polyurethane foams as one of the prime reasons driving the spray polyurethane foam growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the spray polyurethane foam, including some of the vendors such as Armacell International SA, BASF SE, Compagnie de Saint-Gobain SA, Covestro AG, FXI, Huntsman International LLC, LANXESS AG, Nitto Denko Corp., Rogers Corp., and Sekisui Chemical Co. Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the Spray Polyurethane Foam are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

FTC Approves Final Order Settling Charges that Merger of Polyurethane Foam Producers Was Anticompetitive

Retrieved on: 
화요일, 4월 21, 2020
Plastics, Adhesives, Coatings, In science, Polyurethane, Federal Trade Commission, FXI, Foam, Industrial processes, Building materials, Materials

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the merger of polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. would likely substantially lessen competition in three regional markets for the low-density conventional polyurethane foam that is used in home furnishings.

Key Points: 
  • Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the merger of polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. would likely substantially lessen competition in three regional markets for the low-density conventional polyurethane foam that is used in home furnishings.
  • The final order requires the companies to divest FXIs foam-pouring plant in Kent, Washington and Innocors foam-pouring plants in Elkhart, Indiana and Tupelo, Mississippi to Future Foam no later than 10 days after the close of the acquisition.
  • The Commission vote to approve the final order was 5-0.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

FTC Approves Final Order Settling Charges that Merger of Polyurethane Foam Producers Was Anticompetitive

Retrieved on: 
화요일, 4월 21, 2020
Plastics, Adhesives, Coatings, In science, Polyurethane, Federal Trade Commission, FXI, Foam, Industrial processes, Building materials, Materials

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the merger of polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. would likely substantially lessen competition in three regional markets for the low-density conventional polyurethane foam that is used in home furnishings.

Key Points: 
  • Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the merger of polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. would likely substantially lessen competition in three regional markets for the low-density conventional polyurethane foam that is used in home furnishings.
  • The final order requires the companies to divest FXIs foam-pouring plant in Kent, Washington and Innocors foam-pouring plants in Elkhart, Indiana and Tupelo, Mississippi to Future Foam no later than 10 days after the close of the acquisition.
  • The Commission vote to approve the final order was 5-0.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

FTC Requires Polyurethane Foam Producers FXI Holdings, Inc. and Innocor, Inc. To Divest Assets in Three Regional Markets

Retrieved on: 
금요일, 2월 21, 2020
Plastics, Building insulation materials, Corporate crime, Federal Trade Commission, Matter, FXI, Polyurethane, Materials, Physical sciences, Foam

Polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. have agreed to divest polyurethane foam pouring plants in three regional markets to Future Foam, Inc., to settle Federal Trade Commission chargesthat FXIs proposed $850 million acquisition of Innocor would violate federal antitrust law.

Key Points: 
  • Polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. have agreed to divest polyurethane foam pouring plants in three regional markets to Future Foam, Inc., to settle Federal Trade Commission chargesthat FXIs proposed $850 million acquisition of Innocor would violate federal antitrust law.
  • The FTC allegesthat the combination of FXI and Innocor would substantially lessen competition for low-density conventional polyurethane foam used in home furnishings in three regional markets: the Pacific Northwest (Oregon and Washington); the Midwest states of Indiana, Michigan, and Ohio; and Mississippi.
  • The complaint states that regional markets are appropriate because low-density foam is bulky and expensive to ship, relative to the value of the product.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

FTC Requires Polyurethane Foam Producers FXI Holdings, Inc. and Innocor, Inc. To Divest Assets in Three Regional Markets

Retrieved on: 
금요일, 2월 21, 2020
Plastics, Building insulation materials, Corporate crime, Federal Trade Commission, Matter, FXI, Polyurethane, Materials, Physical sciences, Foam

Polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. have agreed to divest polyurethane foam pouring plants in three regional markets to Future Foam, Inc., to settle Federal Trade Commission chargesthat FXIs proposed $850 million acquisition of Innocor would violate federal antitrust law.

Key Points: 
  • Polyurethane foam producers FXI Holdings, Inc. and Innocor, Inc. have agreed to divest polyurethane foam pouring plants in three regional markets to Future Foam, Inc., to settle Federal Trade Commission chargesthat FXIs proposed $850 million acquisition of Innocor would violate federal antitrust law.
  • The FTC allegesthat the combination of FXI and Innocor would substantially lessen competition for low-density conventional polyurethane foam used in home furnishings in three regional markets: the Pacific Northwest (Oregon and Washington); the Midwest states of Indiana, Michigan, and Ohio; and Mississippi.
  • The complaint states that regional markets are appropriate because low-density foam is bulky and expensive to ship, relative to the value of the product.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

Retrieved on: 
수요일, 10월 9, 2019
Coagulation system, Factor XI, Ionis, Factor X, FXI, Coagulation

IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.

Key Points: 
  • IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.
  • "Ionis was first to validate Factor XI and the intrinsic coagulation pathway as a novel antithrombotic strategy.
  • Our antisense medicine targeting Factor XI demonstrates potent antithrombotic activity with little to no bleeding in multiple patient populations.
  • Review of the full data package by Ionis and Bayer is ongoing, and the positive clinical results will be presented at an upcoming medical congress.